AMGN Stock UPDATES Amgen Inc (AMGN) 132.68 08/20/2014 22:58:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amgen Inc (AMGN) 132.68 $AMGN

Final Glance: Biotechnology companies
AP - Wed Aug 20, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:

3 Reasons Gilead Science, Inc.’s Stock Could Rise
Brian Orelli, The Motley Fool - Motley Fool - Wed Aug 20, 4:36PM CDT
Gilead Sciences is trading near all-time highs, but there's still potential for the stock price to go even higher. Here are three things that could send shares higher if they come to fruition. Source: Gilead. 1. Sales of Gilead's...

Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.

Midday Glance: Biotechnology companies
AP - Wed Aug 20, 12:50PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:

Early Glance: Biotechnology companies
AP - Wed Aug 20, 11:21AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.

Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck
PR Newswire - Wed Aug 20, 8:20AM CDT
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Merck (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5855-100free.

Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk
M2 - Wed Aug 20, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6xznb6/global_hormone) has announced the addition of the "Global Hormone Replacement Therapy Market 2014-2018" report to their offering. Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer. The analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018. The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement Therapy. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type of Therapy 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Actavis plc - Bayer AG - Merck & Co. Inc. - Novartis AG - Novo Nordisk A/S - Abbott Laboratories Ltd. - Amgen Inc. - ANI Pharmaceuticals Inc. - Hisamitsu Pharmaceutical Co. Inc. - MylanLaboratories Inc. - Orion Corp. - QuatRx Pharmaceuticals Co. - Teva Pharmaceutical Industries Ltd. - TherapeuticsMD Inc. For more information visit http://www.researchandmarkets.com/research/6x...al_hormone

Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 4:25PM CDT
Amgen Inc. (AMGN) announced that AMG 416 has met the primary as well as secondary endpoints in the second phase III registration study.

14.4% Return Seen to Date on SmarTrend Amgen Call (AMGN)
Comtex SmarTrend(R) - Tue Aug 19, 9:42AM CDT
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on June 2nd, 2014 at $116.45. In approximately 3 months, Amgen has returned 14.41% as of today's recent price of $133.22.

A New Cannabinoid-based Arthritis Therapy in the Making
ACCESSWIRE - Tue Aug 19, 8:50AM CDT
WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based GW Pharmaceuticals plc (NASDAQ: GWPH) have been actively studying cannabinoids since the 1990s, many North American companies haven't started major research until recent years with compounds just starting clinical trials.

Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company
PR Newswire - Tue Aug 19, 12:55AM CDT
Gamida Cell, a world leader in stem cell expansion technologies and therapeutic products, announced today that it has signed an investment and option agreement with Novartis Pharma AG ("Novartis" . According to the agreement, Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and an option to fully acquire Gamida Cell. The option is exercisable for a limited period of time following achievement of certain milestones connected to the development of NiCord®, anticipated to be met during 2015. Completion of the transaction is subject to customary closing conditions.

3 Reasons Amgen, Inc.'s Stock Could Rise
Sean Williams, The Motley Fool - Motley Fool - Mon Aug 18, 5:13PM CDT
As you can see below, Amgen shareholders have had a great three years, with Amgen's stock having risen by more than 160%. AMGN data by YCharts The company's second-quarter earnings results, released three weeks ago, prove testament...

Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis
PR Newswire - Mon Aug 18, 4:17PM CDT
Amgen (NASDAQ:AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as the period between weeks 20 and 27. These results follow the recent announcement of positive data from a prior placebo-controlled Phase 3 study of AMG 416 which was similar in design and size.

Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 4:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized.

Earnings Look Back: Amgen Is Up 7.7% Since Reporting Quarterly Results 2 Weeks Ago (AMGN)
Comtex SmarTrend(R) - Mon Aug 18, 9:32AM CDT
20 days ago, on July 29th, 2014, Amgen (NASDAQ:AMGN) reported its earnings. Analysts, on average, expected earnings of $2.07 per share on sales of $4.9 billion. Amgen actually reported earnings of $2.37 per share on sales of $5.2 billion, beating EPS estimates by $0.30 and beating revenue estimates by $279.7 million. Shares of Amgen have climbed from $123.31 to $132.80, representing a gain of 7.7% since the company reported earnings 20 days ago.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Geothermal AI Nodes Take Aim at Stranded Well Power

Updated Category News Views 48

Millions of idle wells are sitting under America like unwanted basement clutter, and GEIOS GEOFLEX thinks some can become small, self-contained AI power plants. That is the provocative idea behind its Dark Token Factory partnership with Aiden Digital Labs: bolt an autonomous compute module onto an abandoned or non-producing oil and gas well, pull geothermal heat from...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 150

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
JOYY Q3 Growth Shows More Than Livestreaming Muscle

Updated Category News Views 59

Revenue finally has more than one pair of legs at JOYY, and that matters a whole lot more than a flashy quarterly headline. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% from the prior quarter. Those are not microscopic moves, and the composition is the part that deserves the hard stare. JOYY is still rooted in...

Continue Reading
COSCO Shipping Uses CIIE to Put People in the Chain

Updated Category News Views 57

A Supply Chain Is Not Just Steel and Schedules Containers do not shake hands, but the people routing them certainly do. That was the useful, rather human point underneath COSCO SHIPPING's presence at the ninth China International Import Expo in Shanghai: global logistics is a physical business built on relationships that have to survive different languages, markets,...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 43

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 89

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Swell Partners' Awards Highlight Culture, Not Metrics

Updated Category News Views 41

Recognition Lands in a Crowded Talent Market Two shiny Stevie trophies do not pay payroll, but they can say something useful about a company trying to stand out in the noisy talent-services business. Swell Partners has been named 2026 Company of the Year in Business Services and has seen founder and CEO Cari Gatto receive Best Female CEO of the Year. For a private firm...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 77

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 126

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Honda Prelude’s Hybrid Return Tests a Narrow Niche

Updated Category News Views 0

A low-slung coupe showing up in Newfoundland is not exactly a volume-sales thunderclap, and that is precisely why the 2027 Honda Prelude deserves a closer look. Steele Honda in St. John’s is presenting the hybrid two-door as a fresh choice for buyers who want something livelier than the usual practical commuter. For Honda, and for investors watching Honda Motor Co....

Continue Reading

Top 5 Most Recently Viewed Articles

Safety Socket LLC Wins Major Court Ruling Against Counterfeiters

Updated Category News Views 692

Safety Socket LLC Achieves Legal Victory Against Counterfeit Suppliers The jury in a federal court trial has ruled in favor of Safety Socket LLC, confirming that certain fasteners intended for military applications were counterfeit. This significant case, known as Safety Socket LLC v. Relli Technology, Inc., was adjudicated in the U.S. District Court for the Northern...

Continue Reading
Innovative Energy Project Completion in the Gulf of Mexico

Updated Category News Views 244

Completion of McDermott's EPCIC Project in Gulf of Mexico Recently, McDermott celebrated the successful conclusion of its engineering, procurement, construction, installation, and commissioning (EPCIC) project for Shell Offshore Inc., a subsidiary of Shell plc. This project, executed in the Gulf of Mexico, is pivotal in starting oil production at the Whale development....

Continue Reading
Hyperscale Data Plans Major Expansion for AI Infrastructure

Updated Category News Views 365

Significant Power Capacity Increase for Hyperscale Data Hyperscale Data, Inc. (AMEX: GPUS) has recently reported a promising advancement as its subsidiary, Alliance Cloud Services (ACS), has reached a preliminary agreement aimed at boosting the power capacity at its data center. This enhancement, intended to promote growth in artificial intelligence (AI) infrastructure,...

Continue Reading
Global Sewage Crisis Costs $4 Trillion Annually

Updated Category News Views 17

The Overlooked Menace of Sewage Pollution Folks, let me hit you with a harsh reality: while everyone’s chatting about plastic in the ocean or overfishing, there’s a silent disaster slipping under the radar. We’re talking sewage pollution—an issue so vast it's draining the global economy to the tune of $4 trillion each year. That’s what they’re yammering about...

Continue Reading
Inspire Medical Systems, Inc. Class Action Lawsuit Update

Updated Category News Views 231

Inspire Medical Systems, Inc. Investors Take Note The financial landscape for investors is anything but static, particularly for those involved with Inspire Medical Systems, Inc. This article serves as a reminder for investors about the ongoing class action lawsuit, including the critical lead plaintiff deadline. Investors should remain vigilant and informed regarding...

Continue Reading